GLP-1 receptor agonists have become a major focus of metabolic peptide research, particularly for their effects on appetite, glucose regulation, and body weight (Holst; Drucker). However, GLP-1 is not the only hormone involved in these processes. Researchers are also investigating other signaling systems that influence how the body responds to food and regulates energy intake (Alfaris et al.).
Cagrilintide is one such peptide. Unlike GLP-1 receptor agonists, cagrilintide is a long-acting amylin analog designed to reproduce aspects of the natural hormone amylin. Its research focuses primarily on appetite regulation, satiety, and body weight (Lau et al.).
This different mechanism has also made cagrilintide an important component of CagriSema, an investigational combination of cagrilintide and semaglutide (Enebo et al.). By bringing together amylin and GLP-1 receptor signaling, researchers can investigate how these distinct hormonal pathways influence metabolic regulation (Alfaris et al.).
This article explores what cagrilintide is, how amylin signaling works, what distinguishes it from GLP-1-based peptides, and the research behind the CagriSema combination.
What Is Cagrilintide?
Cagrilintide is a synthetic, long-acting peptide analog of amylin, a hormone naturally produced by pancreatic beta cells. It was developed to activate amylin-related receptor pathways involved in appetite regulation and energy balance (Lau et al.).
Unlike naturally occurring amylin, which has a relatively short duration of activity, cagrilintide has been modified to provide prolonged biological activity. This makes it suitable for investigating sustained amylin receptor activation in clinical research (Lau et al.; Enebo et al.).
The cagrilintide peptide has been studied both independently and in combination with semaglutide. Human clinical trials have examined its effects on body weight, appetite-related outcomes, and metabolic regulation in adults with overweight or obesity (Lau et al.).
Its defining feature is its relationship with amylin signaling, a hormonal pathway that differs from the GLP-1 receptor system targeted by many other metabolic peptides (Alfaris et al.).
Understanding Amylin and Its Role in Appetite Regulation
Amylin is a peptide hormone released alongside insulin by pancreatic beta cells, particularly following food intake (Le Foll & Lutz). While insulin primarily helps regulate blood glucose by promoting glucose uptake and storage, amylin contributes to the regulation of food intake and the body's response to a meal (Le Foll & Lutz).
One of amylin's main functions is promoting satiety, the feeling of fullness that helps limit further food consumption. It acts on appetite-regulating pathways in the brain, including regions of the brainstem involved in processing signals related to food intake and energy balance (Lutz; Le Foll & Lutz).
Amylin also slows gastric emptying, regulating the delivery of nutrients after a meal, and suppresses inappropriate post-meal glucagon secretion, a mechanism that does not impair the glucagon response to hypoglycaemia (Lutz; Le Foll & Lutz).
These effects make amylin an important part of the hormonal network controlling appetite and metabolism. Rather than acting through the GLP-1 receptor, it uses a distinct receptor system, providing the biological foundation for the development of amylin analogs such as cagrilintide (Le Foll & Lutz; Lau et al.).
How Does Cagrilintide Work?
The cagrilintide mechanism of action centers on the activation of amylin-related receptors. These receptors consist of a calcitonin receptor associated with proteins called receptor activity-modifying proteins (RAMPs), which influence how the receptor responds to different hormones (Le Foll & Lutz; Lau et al.).
Cagrilintide is a long-acting amylin analog with activity at amylin and calcitonin receptors. Its appetite-regulating effects are thought to involve signaling pathways in the brain, particularly the area postrema and nucleus of the solitary tract. These brainstem regions help process hormonal signals related to food intake and satiety (Le Foll & Lutz; Lutz).
Through these pathways, amylin-based signaling can influence meal size and the feeling of fullness (Lutz). Cagrilintide is designed to produce sustained receptor activation, allowing researchers to investigate how prolonged amylin-related signaling affects appetite and body weight (Lau et al.).
Human clinical trials have reported reductions in body weight during cagrilintide treatment (Lau et al.). However, the precise contribution of individual receptor subtypes and neural pathways to these outcomes remains an area of ongoing research (Le Foll & Lutz).
Why Cagrilintide Represents a Different Approach
Most widely studied metabolic peptides, including semaglutide, target the glucagon-like peptide-1 (GLP-1) receptor (Holst; Drucker). Cagrilintide takes a different approach by engaging the amylin receptor system, offering another way to investigate the hormonal regulation of appetite and energy intake (Le Foll & Lutz; Lau et al.).
Although both pathways influence satiety and food consumption, they differ in several important ways:
- Different hormonal origins: GLP-1 is primarily released by intestinal endocrine cells in response to nutrients (Holst), while amylin is released alongside insulin by pancreatic beta cells (Le Foll & Lutz).
- Different receptor systems: GLP-1 receptor agonists activate the GLP-1 receptor (Drucker). Cagrilintide acts through amylin-related and calcitonin receptor pathways, which have distinct molecular structures and signaling characteristics (Le Foll & Lutz).
- Partly distinct neural pathways: Both hormones influence appetite-regulating networks in the brain, but they engage these networks through different receptor populations and signaling mechanisms (Lutz; Cabou & Burcelin).
These differences do not mean that the two pathways operate independently. Amylin and GLP-1 signaling can influence overlapping aspects of appetite regulation, including satiety and meal-related responses (Le Foll & Lutz; Lau et al.).
This overlap is particularly interesting in metabolic research. Combining two distinct hormonal mechanisms may produce effects that differ from activating either pathway alone. This provides the scientific rationale for investigating cagrilintide alongside GLP-1 receptor agonists, particularly semaglutide in the CagriSema combination (Enebo et al.; Alfaris et al.).
Cagrilintide Benefits and Applications in Research
Research into the cagrilintide peptide benefits primarily focuses on appetite regulation, body weight, and metabolic function (Lau et al.; Le Foll & Lutz). As a long-acting amylin analog, cagrilintide provides an opportunity to investigate how sustained amylin-related signaling influences these processes (Lau et al.).
Several areas have attracted particular research interest:
- Appetite and satiety regulation: Amylin signaling contributes to feelings of fullness and the regulation of food intake (Lutz). Cagrilintide research investigates how prolonged activation of this pathway may influence appetite-related responses and energy consumption (Lau et al.).
- Body weight regulation: Clinical studies have reported reductions in body weight with cagrilintide, supporting continued investigation of amylin-based signaling in weight regulation and energy balance (Lau et al.).
- Glucose and metabolic regulation: Natural amylin contributes to post-meal glucose regulation through effects on gastric emptying and glucagon secretion (Le Foll & Lutz). Cagrilintide research explores the broader metabolic implications of activating this hormonal pathway, although its glucose-related effects should not be assumed to match those of GLP-1 receptor agonists (Holst).
- Combination-based metabolic research: Cagrilintide is also being investigated alongside semaglutide to examine the effects of targeting amylin and GLP-1 signaling together. This approach forms the basis of CagriSema, an investigational combination designed to engage both pathways (Enebo et al.; Alfaris et al.).
These research areas highlight the growing interest in amylin-based approaches to metabolic regulation. Clinical findings support cagrilintide's effects on body weight, while its broader metabolic mechanisms and potential applications remain subjects of ongoing investigation (Lau et al.; Le Foll & Lutz).
What Is CagriSema? Combining Cagrilintide and Semaglutide
CagriSema is an investigational combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist. It brings together two distinct hormonal pathways involved in appetite regulation and metabolic function (Enebo et al.).
While cagrilintide activates amylin-related receptor pathways (Le Foll & Lutz), semaglutide targets the GLP-1 receptor, influencing appetite, insulin secretion, and glucose regulation (Knudsen & Lau; Drucker). Combining these mechanisms allows researchers to investigate whether simultaneous activation produces greater effects than either pathway alone (Enebo et al.; Alfaris et al.).
Clinical studies have reported greater average body weight reductions with CagriSema than with either component individually (Enebo et al.). These findings highlight the potential of combining amylin and GLP-1 signaling, although further research is needed to understand their respective contributions to the observed effects (Le Foll & Lutz).
Where to Get Cagrilintide for Research
Researchers sourcing cagrilintide peptide should consider peptide identity, purity, batch consistency, and access to appropriate testing documentation. These factors help establish the quality and reproducibility of materials used in laboratory investigations.
Polaris Peptides offers cagrilintide as an individual research compound and as part of a Cagrilintide/Semaglutide blend. Both options are intended for laboratory research, providing materials for investigating amylin-related signaling independently or alongside GLP-1 receptor activation. These compounds are not intended for human or veterinary use.
Conclusion
Cagrilintide represents a different approach to appetite and metabolic research by targeting amylin-related signaling rather than the GLP-1 receptor. Its distinct mechanism provides another way to investigate how hormonal signals influence satiety, food intake, and body weight regulation.
Clinical research has reported reductions in body weight with cagrilintide, while studies of CagriSema have explored the effects of combining amylin and GLP-1 receptor activation. Together, these findings highlight the growing interest in metabolic approaches that extend beyond GLP-1 signaling alone.

